



MEDICAL ONCOLOGY Blueprint

For traditional, 10-year Maintenance of Certification (MOC) exam and Longitudinal Knowledge Assessment (LKA®)

ABIM invites diplomates to help develop the Medical Oncology MOC exam blueprint

Based on feedback from physicians that MOC assessments should better reflect what they see in practice, in 2016 the American Board of Internal Medicine (ABIM) invited all certified medical oncologists to provide ratings of the relative frequency and importance of blueprint topics in practice.

This review process, which resulted in a new MOC exam blueprint, will be used on an ongoing basis to inform and update all MOC assessments created by ABIM. No matter what form ABIM's assessments ultimately take, they will need to be informed by front-line clinicians sharing their perspective on what is important to know.

A sample of over 300 medical oncologists, similar to the total invited population of medical oncologists in age, gender, geographic region, and time spent in direct patient care, provided the blueprint topic ratings. ABIM used this feedback to update the blueprint for the MOC assessment (beginning with the Fall 2016 administration).

To inform how assessment content should be distributed across the major blueprint content categories, ABIM considered the average respondent ratings of topic frequency and importance in each of the content categories. A second source of information was the relative frequency of patient conditions in the content categories, as seen by certified medical oncologists and documented by national health care data (described further under *Content distribution* below).

To determine prioritization of specific assessment content within each major medical content category, ABIM used the respondent ratings of topic frequency and importance to set thresholds for these parameters in the exam assembly process (described further under *Detailed content outline* below).

Purpose of the Medical Oncology MOC Assessments

The MOC assessment is designed to evaluate whether a certified medical oncologist has maintained competence and currency in the knowledge and judgment required for practice. The MOC assessment emphasizes diagnosis and management of prevalent conditions, particularly in areas where practice has changed in recent years. As a result of the blueprint review by ABIM diplomates, future assessments place less emphasis on rare conditions and focus more on situations in which physician intervention can have important consequences for patients. For conditions that are usually managed by other specialists, the focus will be on recognition rather than on management.

Assessment format

The traditional, 10-year MOC exam is composed of 220 single-best-answer multiple-choice questions, of which approximately 50 are new questions that do not count in the examinee's score. Examinees taking the traditional, 10-year MOC assessment will have access to an external resource (i.e., UpToDate®) for the entire exam.

The LKA for MOC, is a five-year cycle in which physicians answer questions on an ongoing basis and receive feedback on how they're performing along the way. More information on how exams are developed can be found at abim.org/about/exam-information/exam-development.aspx.

Most questions describe patient scenarios and ask about the work done (that is, tasks performed) by physicians in the course of practice:

- **Diagnosis:** making a diagnosis or identifying an underlying condition
- **Testing:** ordering tests for diagnosis, staging, or follow-up
- **Treatment/Care Decisions:** recommending treatment or other patient care
- **Risk Assessment/Prognosis/Epidemiology:** assessing risk, determining prognosis, and applying principles from epidemiologic studies
- **Pathophysiology/Basic Science:** understanding the pathophysiology of disease and basic science knowledge applicable to patient care

ABIM is committed to working toward health equity and believes that board-certified physicians should have an understanding of health care disparities. Therefore, health equity content that is clinically important to each discipline will be included in assessments, and the use of gender, race, and ethnicity identifiers will be re-evaluated.

Reflecting the overall predominance of office-based practice, most questions describe patient encounters that take place in outpatient settings; some encounters will occur in hospital or other inpatient settings because most medical oncologists provide patient care in these settings as well.

Clinical information presented may include patient photographs, radiographs, computed tomograms, photomicrographs, magnetic resonance images, an equianalgesic table, bone scans, family pedigree charts, nomograms, and other media to illustrate relevant patient findings.

Exam tutorials, including examples of question format, can be found at abim.org/maintenance-of-certification/exam-information/medical-oncology/exam-tutorial.aspx.

Content distribution

Listed below are the major medical content categories that define the domain for the Medical Oncology traditional, 10-year MOC and LKA. The relative distribution of content is expressed as a percentage of the total assessment. To determine the content distribution, ABIM considered the average respondent

| CONTENT CATEGORY | TARGET % |
|--|-------------|
| Anticancer Therapeutics, Clinical Research Methodology, and Ethics | 9.5% |
| Palliative Care, Survivorship, and Communication | 11% |
| Genetics, Genomics, and Tumor Biology | 2% |
| Hematologic Neoplasms | 14% |
| Thoracic Cancer | 11% |
| Breast Cancer | 13% |
| Genitourinary Cancer | 12% |
| Gynecologic Cancer | 4% |
| Gastrointestinal Cancer | 13.5% |
| Skin Cancer, Sarcomas, and Unknown Primary Site | 6% |
| Head, Neck, Thyroid, and Central Nervous System Malignancies | 4% |
| Total | 100% |

ratings of topic frequency and importance. To cross-validate these self-reported ratings, ABIM also considered the relative frequency of conditions seen in Medicare patients by a cohort of certified medical oncologists. Informed by these data, the Medical Oncology Approval Committee and Board have determined the content category targets shown below.

How the blueprint ratings are used to assemble the MOC assessment

Blueprint reviewers provided ratings of relative frequency in practice for each of the detailed content topics in the blueprint and provided ratings of the relative importance of the topics for each of the tasks described in *Assessment format* above. In rating importance, reviewers were asked to consider factors such as the following:

- High risk of a significant adverse outcome
- Cost of care and stewardship of resources
- Common errors in diagnosis or management
- Effect on population health
- Effect on quality of life
- When failure to intervene by the physician deprives a patient of significant benefit

Frequency and importance were rated on a three-point scale corresponding to low, medium, or high. The median importance ratings are reflected in the *Detailed content outline* below.

The Medical Oncology Approval Committee and Medical Oncology Board, in partnership with the physician community, have set the following parameters for selecting MOC assessment questions according to the blueprint review ratings:

- At least 75% of questions will address high-importance content (indicated in green)
- No more than 25% of questions will address medium-importance content (indicated in yellow)
- No exam questions will address low-importance content (indicated in red)

Independent of the importance and task ratings, no more than 20% of questions will address low-frequency content (indicated by “LF” following the topic description).

The content selection priorities below are applicable beginning with the Fall 2016 traditional, 10-year MOC exam and are subject to change in response to future blueprint review.

Note: The same topic may appear in more than one medical content category.

Detailed content outline for the Medical Oncology traditional, 10-year MOC exam and LKA

| | | |
|--|--|--|
|  – High Importance: At least 75% of questions will address topics and tasks with this designation. |  – Medium Importance: No more than 25% of questions will address topics and tasks with this designation. |  – Low Importance: No questions will address topics and tasks with this designation. |
| LF – Low Frequency: No more than 20% of questions will address topics with this designation, regardless of task or importance. | | |

| ANTICANCER THERAPEUTICS, CLINICAL RESEARCH METHODOLOGY, AND ETHICS (9.5% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

PRINCIPLES OF ALLIED DISCIPLINES (<2% of exam)

| | | | | | |
|--------------------------|--|--|--|--|--|
| Surgical oncology |  |  |  |  |  |
| Radiation oncology |  |  |  |  |  |
| Interventional radiology |  |  |  |  |  |
| Pathology |  |  |  |  |  |

ANTICANCER THERAPEUTICS (8% of exam)

| | | | | | |
|---|---|---|---|---|---|
| Cytotoxic chemotherapy agents | | | | | |
| Alkylating agents |  |  |  |  |  |
| Antimetabolites |  |  |  |  |  |
| Antitubulin agents |  |  |  |  |  |
| Anthracyclines |  |  |  |  |  |
| Topoisomerase I inhibitors |  |  |  |  |  |
| Topoisomerase II inhibitors |  |  |  |  |  |
| Bleomycin and other DNA-damaging agents |  |  |  |  |  |
| Chemotherapy-drug interactions |  |  |  |  |  |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| ANTICANCER THERAPEUTICS, CLINICAL RESEARCH METHODOLOGY, AND ETHICS <i>continued...</i> (9.5% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

ANTICANCER THERAPEUTICS *continued...* (8% of exam)

| | | | | | |
|---|------|---|---|---|---|
| Hormonal therapies | | | | | |
| Estrogens and selective estrogen response modifiers | ✔ | ✔ | ✔ | ✔ | ✔ |
| Progestins and antiprogestins | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Aromatase inhibitors | ✔ | ✔ | ✔ | ✔ | ✔ |
| Androgens and antiandrogens | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Gonadotropin-releasing hormone analogues | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Glucocorticoids | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Small molecule kinase inhibitors | | | | | |
| BCR-ABL1 inhibitors | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Epidermal growth factor receptor (EGFR) inhibitors | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Vascular endothelial growth factor receptor (VEGFR)/multitargeted inhibitors | ✔ | ✔ | ✔ | ✔ | ⚠ |
| BRAF inhibitors | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Anaplastic lymphoma kinase (ALK) and mesenchymal epithelial transition (MET) growth factor inhibitors | LF ⚠ | ⚠ | ✔ | ⚠ | ⚠ |
| RET, ROS1, and NTRK inhibitors | LF ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Mitogen-activated protein kinase (MEK) inhibitors | LF ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Bruton's tyrosine kinase (BTK) inhibitors | ⚠ | ⚠ | ✔ | ⚠ | ⚠ |
| Janus kinase (JAK) inhibitors | ✔ | ⚠ | ✔ | ⚠ | ⚠ |
| Phosphoinositide-3 kinase (PI3K) inhibitors | LF ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Mammalian target of rapamycin (mTOR)/AKT inhibitors | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Cyclin-dependent kinase (CDK) inhibitors | LF ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| ANTICANCER THERAPEUTICS, CLINICAL RESEARCH METHODOLOGY, AND ETHICS <i>continued...</i> (9.5% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

ANTICANCER THERAPEUTICS *continued...* (8% of exam)

| | | | | | |
|--|----|---|---|---|---|
| Agents with epigenetic activity | | | | | |
| Histone deacetylase (HDAC) inhibitors | LF | ⚠ | ⚠ | ⚠ | ⚠ |
| DNA methyltransferase inhibitors | LF | ⚠ | ⚠ | ⚠ | ⚠ |
| Metabolic inhibitors other than antimetabolites | LF | ⚠ | ⚠ | ⚠ | ✘ |
| Monoclonal antibodies and antibody conjugates other than immune checkpoint inhibitors | | | | | |
| Monoclonal antibodies targeting EGFR, HER2, HER3 | | ✔ | ✔ | ✔ | ✔ |
| Monoclonal antibodies targeting VEGFR pathway | | ✔ | ✔ | ✔ | ⚠ |
| Monoclonal antibodies targeting B cell antigens (including CD20) | | ✔ | ✔ | ✔ | ⚠ |
| Bispecific monoclonal antibodies | LF | ⚠ | ⚠ | ⚠ | ⚠ |
| Monoclonal antibody immune checkpoint inhibitors | | | | | |
| Agents targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) | LF | ⚠ | ⚠ | ⚠ | ⚠ |
| Agents targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) | | ✔ | ✔ | ✔ | ⚠ |
| Tumor vaccines and viral-based immunotherapeutics | LF | ⚠ | ⚠ | ⚠ | ✘ |
| Agents with other novel or specific targets | | | | | |
| Proteasome inhibitors | | ✔ | ✔ | ✔ | ⚠ |
| Immunomodulatory drugs (IMiDs) | | ✔ | ✔ | ✔ | ⚠ |
| Poly(ADP-ribose) polymerase (PARP) inhibitors | LF | ⚠ | ⚠ | ⚠ | ⚠ |
| Arsenicals | LF | ⚠ | ⚠ | ⚠ | ✘ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| ANTICANCER THERAPEUTICS, CLINICAL RESEARCH METHODOLOGY, AND ETHICS <i>continued...</i> (9.5% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|-----------|---------|------------------------------|--|-----------------------------------|
|--|-----------|---------|------------------------------|--|-----------------------------------|

ANTICANCER THERAPEUTICS *continued...* (8% of exam)

| | | | | | |
|--|---|---|---|---|---|
| Cellular therapeutics | | | | | |
| High-dose therapy with stem cell rescue (autologous and allogeneic) LF | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Chimeric antigen receptor (CAR) T-cell therapy LF | ✘ | ✘ | ✘ | ✘ | ✘ |

CLINICAL RESEARCH METHODOLOGY AND ETHICS (<2% of exam)

| | | | | | |
|--|----------------|---|---|---|---|
| Clinical research methodology | | | | | |
| Design and interpretation of clinical trials | Not Applicable | | | ⚠ | ⚠ |
| Tumor assessment, imaging, and end points | ✔ | ✔ | ✔ | ⚠ | ⚠ |

| | | | | | |
|--|---|---|---|---|----------------|
| Ethics | | | | | |
| Human subjects and regulatory and legal issues | ⚠ | ⚠ | ⚠ | ⚠ | Not Applicable |
| Conflict of interest | ⚠ | ⚠ | ⚠ | ⚠ | Not Applicable |

| PALLIATIVE CARE, SURVIVORSHIP, AND COMMUNICATION (11% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|-----------|---------|------------------------------|--|-----------------------------------|
|--|-----------|---------|------------------------------|--|-----------------------------------|

CLINICAL MANIFESTATIONS OF ADVANCED CANCER AND ITS TREATMENT (4.5% of exam)

| | | | | | |
|---|---|---|---|---|---|
| Cutaneous and mucosal manifestations | ✔ | ⚠ | ✔ | ⚠ | ⚠ |
| Endocrine manifestations | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Gastrointestinal manifestations | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Hematologic manifestations | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Musculoskeletal manifestations | ✔ | ⚠ | ✔ | ⚠ | ⚠ |
| Neurologic manifestations* | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Renal, metabolic, and nutritional manifestations* | ✔ | ⚠ | ✔ | ⚠ | ⚠ |
| Paraneoplastic syndromes LF | ✔ | ⚠ | ✔ | ⚠ | ⚠ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

◐ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| PALLIATIVE CARE, SURVIVORSHIP, AND COMMUNICATION <i>continued...</i> (11% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

CLINICAL MANIFESTATIONS OF ADVANCED CANCER AND ITS TREATMENT *continued...* (4.5% of exam)

| | | | | | |
|------------------------------------|----|----|----|----|----|
| Cardiothoracic manifestations | ✔ | ✔ | ✔ | ◐ | ◐ |
| Fatigue | ✔ | ✔ | ✔ | ◐ | ◐ |
| Psychiatric manifestations | ✔ | ◐ | ✔ | ◐ | ✘ |
| Infectious risks and complications | ✔ | ✔ | ✔ | ✔ | ◐ |
| Lymphedema | ✔* | ✔* | ✔* | ◐* | ✘* |

CANCER PAIN (2% of exam)

| | | | | | |
|-------------------|---|---|---|---|---|
| Use of opioids | ✔ | ✔ | ✔ | ◐ | ◐ |
| Use of nonopioids | ✔ | ◐ | ✔ | ◐ | ◐ |

SURVIVORSHIP ISSUES (<2% of exam)

| | | | | | |
|-----------------------------|---|---|---|---|---|
| Fertility and Sexual Health | ◐ | ◐ | ✔ | ◐ | ✘ |
| Second primary cancers | ✔ | ✔ | ✔ | ◐ | ◐ |
| Secondary cancer prevention | ✔ | ✔ | ✔ | ◐ | ◐ |
| Nonmalignant sequelae | ◐ | ◐ | ◐ | ◐ | ◐ |
| Surveillance | ✔ | ✔ | ✔ | ✔ | ✘ |

END-OF-LIFE ISSUES (2% of exam)

| | | | | | |
|-------------------------------|---|---|---|---|---|
| Hospice | ✔ | ✔ | ✔ | ✔ | ✘ |
| Feeding and nutrition | ✔ | ◐ | ✔ | ◐ | ◐ |
| Decision making/communication | ✔ | ✔ | ✔ | ✔ | ◐ |

PROCEDURE-RELATED ISSUES (<2% of exam)

| | | | | | |
|--|---|---|---|---|---|
| Chemotherapy administration | ✔ | ✔ | ✔ | ✔ | ◐ |
| Bone marrow aspiration, biopsy, and interpretation | ✔ | ✔ | ✔ | ✔ | ◐ |
| Tumor assessment | ✔ | ✔ | ✔ | ◐ | ◐ |
| Thoracentesis | ◐ | ◐ | ◐ | ◐ | ✘ |
| Paracentesis | ◐ | ◐ | ◐ | ◐ | ◐ |
| Feeding tubes | ◐ | ◐ | ◐ | ◐ | ✘ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| PALLIATIVE CARE, SURVIVORSHIP, AND COMMUNICATION <i>continued...</i> (11% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|-----------|---------|------------------------------|--|-----------------------------------|
|--|-----------|---------|------------------------------|--|-----------------------------------|

COMMUNICATION (<2% of exam)

| | | | | | |
|--|----------------|--|---|----------------|--|
| Communicating prognosis and other clinical information | Not Applicable | | ✔ | Not Applicable | |
| Discussing goals of care | Not Applicable | | ✔ | Not Applicable | |
| Discussing survivorship issues | Not Applicable | | ✔ | Not Applicable | |

| GENETICS, GENOMICS, AND TUMOR BIOLOGY (2% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|-----------|---------|------------------------------|--|-----------------------------------|
|--|-----------|---------|------------------------------|--|-----------------------------------|

CANCER BIOLOGY AND GENETICS (<2% of exam)

| | | | | | | |
|----------------|----|---|---|---|---|---|
| Carcinogenesis | LF | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Genomics | | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |

TUMOR IMMUNOLOGY (<2% of exam)

| | | | | | | |
|------------------|--|---|---|---|---|---|
| Tumor immunology | | ⚠ | ⚠ | ✔ | ✘ | ⚠ |
|------------------|--|---|---|---|---|---|

HERITABLE CANCER SYNDROMES (<2% of exam)

| | | | | | | |
|-----------------------------|----|---|---|---|---|---|
| Li-Fraumeni syndrome (TP53) | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| BRCA1 and BRCA2 syndromes | | ✔ | ✔ | ✔ | ✔ | ⚠ |

Familial colorectal cancer

| | | | | | | |
|--|----|---|---|---|---|---|
| Familial adenomatous polyposis | LF | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Lynch syndrome (hereditary nonpolyposis colorectal cancer) | | ✔ | ✔ | ✔ | ⚠ | ⚠ |

| | | | | | | |
|--|----|---|---|---|---|---|
| Multiple endocrine neoplasia and familial medullary thyroid cancer syndromes | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
|--|----|---|---|---|---|---|

CANCER EPIDEMIOLOGY (<2% of exam)

| | | | | | | |
|---------------------|--|---|---|---|---|---|
| Cancer epidemiology | | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
|---------------------|--|---|---|---|---|---|

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

◐ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – Low Frequency: No more than 20% of questions will address topics with this designation, regardless of task or importance.

| HEMATOLOGIC NEOPLASMS (14% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|-----------|---------|------------------------------|--|-----------------------------------|
|--|-----------|---------|------------------------------|--|-----------------------------------|

ACUTE LEUKEMIA AND MYELOYDYSPLASIA (3% of exam)

| | | | | | |
|---|---|---|---|---|---|
| Acute myeloid leukemia (AML) | | | | | |
| Acute promyelocytic leukemia (APL) LF | ✔ | ✔ | ✔ | ◐ | ◐ |
| AML with recurrent genetic abnormalities LF | ✔ | ✔ | ◐ | ◐ | ◐ |
| AML with myelodysplasia-related changes | ✔ | ◐ | ✔ | ◐ | ◐ |
| AML not otherwise specified LF | ✔ | ✔ | ◐ | ◐ | ◐ |
| Myeloid sarcoma LF | ◐ | ◐ | ◐ | ✘ | ✘ |
| Acute lymphoblastic leukemia/lymphoma LF | ✔ | ✔ | ◐ | ◐ | ◐ |
| Myelodysplastic syndromes | ✔ | ✔ | ✔ | ✔ | ◐ |
| Chronic myelomonocytic leukemia | ✔ | ◐ | ◐ | ◐ | ◐ |

CHRONIC MYELOID LEUKEMIA AND MYELOPROLIFERATIVE NEOPLASMS (2% of exam)

| | | | | | |
|------------------------------|---|---|---|---|---|
| Chronic myeloid leukemia | ✔ | ✔ | ✔ | ✔ | ◐ |
| Myeloproliferative neoplasms | ✔ | ✔ | ✔ | ◐ | ◐ |

CHRONIC LYMPHOPROLIFERATIVE LEUKEMIAS (2% of exam)

| | | | | | |
|---|---|---|---|---|---|
| Chronic lymphocytic leukemia/ small lymphocytic lymphoma | ✔ | ✔ | ✔ | ✔ | ◐ |
| Hairy cell leukemia LF | ✔ | ◐ | ✔ | ◐ | ◐ |
| T-cell prolymphocytic leukemia LF | ◐ | ◐ | ◐ | ✘ | ✘ |
| T-cell large granular lymphocytic leukemia LF | ◐ | ◐ | ◐ | ✘ | ✘ |
| Monoclonal B-cell lymphocytosis | ◐ | ◐ | ◐ | ◐ | ✘ |

HODGKIN LYMPHOMA (<2% of exam)

| | | | | | |
|---------------------|---|---|---|---|---|
| Early-stage disease | ✔ | ✔ | ✔ | ✔ | ◐ |
| Advanced disease | ✔ | ✔ | ✔ | ◐ | ◐ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| HEMATOLOGIC NEOPLASMS <i>continued...</i> (14% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

MULTIPLE MYELOMA AND PLASMA CELL DYSCRASIAS (2% of exam)

| | | | | | |
|---|---|---|---|---|---|
| Multiple myeloma/plasma cell leukemia | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Solitary plasmacytoma LF | ⚠ | ⚠ | ✔ | ⚠ | ⚠ |
| Primary amyloidosis LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Monoclonal gammopathy of undetermined significance (MGUS) | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Lymphoplasmacytic lymphoma (including Waldenstrom macroglobulinemia) LF | ✔ | ✔ | ✔ | ⚠ | ⚠ |

NON-HODGKIN LYMPHOMA (4% of exam)

| | | | | | |
|--|---|---|---|---|---|
| Diffuse large B-cell lymphoma | ✔ | ✔ | ✔ | ✔ | ✘ |
| Follicular lymphoma | ✔ | ✔ | ✔ | ✔ | ✘ |
| Burkitt lymphoma | ✔ | ✔ | ✔ | ⚠ | ✘ |
| Mantle cell lymphoma | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| NK-T cell lymphoma LF | ⚠ | ⚠ | ⚠ | ✘ | ✘ |
| Anaplastic large cell lymphoma LF | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) | ✔ | ⚠ | ✔ | ⚠ | ⚠ |
| Nodal marginal zone lymphoma | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Human immunodeficiency virus (HIV)-associated lymphoma LF | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Cutaneous T-cell lymphoma LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Primary central nervous system lymphoma LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Post-transplantation lymphoproliferative syndromes LF | ⚠ | ⚠ | ⚠ | ✘ | ✘ |
| Peripheral T-cell lymphoma LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

◐ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – Low Frequency: No more than 20% of questions will address topics with this designation, regardless of task or importance.

| THORACIC CANCER (11% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

NON-SMALL CELL LUNG CANCER (9% of exam)

| | | | | | |
|--------------------------|----|----|----|----|----|
| Early-stage disease | ✔ | ✔ | ✔ | ✔ | ◐ |
| Locally advanced disease | | | | | |
| Stage IIIA disease | ✔ | ✔ | ✔ | ✔ | ◐ |
| Stage IIIB disease | ✔ | ✔ | ✔ | ✔ | ◐ |
| Stage IIIC disease | ✔ | ✔ | ✔ | ✔ | ◐ |
| Metastatic disease | | | | | |
| Adenocarcinoma | ✔* | ✔* | ✔* | ◐* | ◐* |
| Squamous cell carcinoma | ✔* | ✔* | ✔* | ◐* | ◐* |

SMALL CELL LUNG CANCER (<2% of exam)

| | | | | | |
|-------------------|---|---|---|---|---|
| Limited disease | ✔ | ✔ | ✔ | ✔ | ◐ |
| Extensive disease | ✔ | ✔ | ✔ | ✔ | ◐ |

MESOTHELIOMA AND THYMUS CANCER (<2% of exam)

| | | | | | | |
|---------------|----|---|---|---|---|---|
| Mesothelioma | LF | ✔ | ✔ | ✔ | ◐ | ◐ |
| Thymus cancer | LF | ◐ | ◐ | ◐ | ◐ | ✘ |

| BREAST CANCER (13% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---------------------------------------|-----------|---------|------------------------------|--|-----------------------------------|
|---------------------------------------|-----------|---------|------------------------------|--|-----------------------------------|

PREMALIGNANT CONDITIONS AND HIGH-RISK FACTORS (<2% of exam)

| | | | | | |
|--|---|---|---|---|---|
| High-risk histologies (including atypical ductal hyperplasia and atypical lobular hyperplasia) | ✔ | ✔ | ✔ | ✔ | ◐ |
| Genetic predispositions | ◐ | ✔ | ✔ | ✔ | ◐ |

CARCINOMA IN SITU (<2% of exam)

| | | | | | |
|-------------------|---|---|---|---|---|
| Carcinoma in situ | ✔ | ✔ | ✔ | ✔ | ◐ |
|-------------------|---|---|---|---|---|

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| BREAST CANCER <i>continued...</i> (13% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|------------------|----------------|--------------------------------------|---|---|
|--|------------------|----------------|--------------------------------------|---|---|

EARLY-STAGE AND LOCALLY ADVANCED INVASIVE CARCINOMA (4.5% of exam)

| | | | | | |
|--|----|----|----|----|----|
| HER2-positive disease | ✔* | ✔* | ✔* | ⚠* | ⚠* |
| HER2-negative, hormone receptor-positive disease | ✔* | ✔* | ✔* | ⚠* | ⚠* |
| HER2-negative, hormone receptor-negative (triple-negative) disease | ✔* | ✔* | ✔* | ✔* | ✔* |

INFLAMMATORY DISEASE (<2% of exam)

| | | | | | |
|----------------------|---|---|---|---|---|
| Inflammatory disease | ✔ | ✔ | ✔ | ✔ | ⚠ |
|----------------------|---|---|---|---|---|

LOCALLY RECURRENT DISEASE (<2% of exam)

| | | | | | |
|---------------------------------|---|---|---|---|---|
| In-breast recurrence | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Chest wall recurrence LF | ✔ | ✔ | ✔ | ⚠ | ⚠ |

METASTATIC DISEASE (4.5% of exam)

| | | | | | |
|---|----|----|----|----|----|
| HER2-positive metastatic disease | ✔* | ✔* | ✔* | ⚠* | ⚠* |
| HER2-negative, hormone receptor-positive metastatic disease | ✔* | ✔* | ✔* | ⚠* | ⚠* |
| HER2-negative, hormone receptor-negative (triple-negative) metastatic disease | ✔* | ✔* | ✔* | ✔* | ✔* |

LESS COMMON CLINICAL SCENARIOS (<2% of exam)

| | | | | | |
|------------------------------------|----|----|----|----|----|
| Tubular carcinoma LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Male breast cancer LF | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Pregnancy-associated breast cancer | ✔* | ✔* | ✔* | ⚠* | ✘* |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| GENITOURINARY CANCER (12% of exam) | | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|--|------------------|----------------|--------------------------------------|---|---|
|--|--|------------------|----------------|--------------------------------------|---|---|

GERM CELL TUMORS (<2% of exam)

| | | | | | | |
|------------------------------------|----|---|---|---|---|---|
| Seminoma | LF | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Nonseminoma | LF | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Germ cell tumor type not specified | LF | ✔ | ✔ | ✔ | ⚠ | ⚠ |

PROSTATE CANCER (5% of exam)

| | | | | | | |
|--------------------------|--|---|---|---|---|---|
| Localized disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Locally advanced disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |

Prostate-specific antigen-only nonmetastatic disease

| | | | | | | |
|------------------------------|--|----|----|----|----|----|
| Castration-sensitive disease | | ✔* | ✔* | ✔* | ⚠* | ⚠* |
| Castration-resistant disease | | ✔* | ✔* | ✔* | ⚠* | ⚠* |

Metastatic disease

| | | | | | | |
|---|--|---|---|---|---|---|
| Metastatic castration-sensitive disease | | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Metastatic castration-resistant disease | | ✔ | ✔ | ✔ | ✔ | ⚠ |

Special issues in prostate cancer

| | | | | | | |
|----------------------|----|---|---|---|---|---|
| Small cell carcinoma | LF | ⚠ | ⚠ | ✔ | ⚠ | ✘ |
|----------------------|----|---|---|---|---|---|

RENAL CELL CANCER (2.5% of exam)

| | | | | | | |
|-------------------------------------|--|---|---|---|---|---|
| Localized disease | | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Metastatic disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Special issues in renal cell cancer | | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |

UROTHELIAL AND OTHER GENITOURINARY CANCERS (2.5% of exam)

| | | | | | | |
|-----------------------------|----|---|---|---|---|---|
| Bladder cancer | | | | | | |
| Non-muscle invasive disease | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Muscle-invasive disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Metastatic disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – Low Frequency: No more than 20% of questions will address topics with this designation, regardless of task or importance.

| GENITOURINARY CANCER <i>continued...</i> (12% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|------------------|----------------|--------------------------------------|---|---|
|---|------------------|----------------|--------------------------------------|---|---|

UROTHELIAL AND OTHER GENITOURINARY CANCERS *continued... (2.5% of exam)*

| | | | | | |
|------------------------------------|---|---|---|---|---|
| Other urothelial cancers | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Adrenal tumors | | | | | |
| Adrenocortical carcinoma | ✘ | ✘ | ✘ | ✘ | ✘ |
| Pheochromocytoma and paraganglioma | ⚠ | ✘ | ✘ | ✘ | ✘ |

| GYNECOLOGIC CANCER (4% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|------------------|----------------|--------------------------------------|---|---|
|---|------------------|----------------|--------------------------------------|---|---|

CERVICAL CANCER (<2% of exam)

| | | | | | | |
|--|----|---|---|---|---|---|
| Local-regional disease (Stages II and III) | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Recurrent and metastatic disease | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |

OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCERS (2% of exam)

| | | | | | | |
|--|----|---|---|---|---|---|
| Epithelial ovarian, fallopian tube, and primary peritoneal cancers | | | | | | |
| Stage I | LF | ⚠ | ⚠ | ✔ | ⚠ | ⚠ |
| Stages II–IV | | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Nonepithelial ovarian cancers | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Low malignant potential (borderline) cancers | LF | ⚠ | ✘ | ⚠ | ✘ | ✘ |

OTHER GYNECOLOGIC MALIGNANCIES (<2% of exam)

| | | | | | | |
|-----------------------------------|----|---|---|---|---|---|
| Uterine sarcoma | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Gestational trophoblastic disease | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Cancers of the vulva and vagina | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| GASTROINTESTINAL CANCER (13.5% of exam) | | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|--|------------------|----------------|--------------------------------------|---|---|
|---|--|------------------|----------------|--------------------------------------|---|---|

ANAL CANCER (<2% of exam)

| | | | | | | |
|----------------------------------|----|---|---|---|---|---|
| Local-regional disease | LF | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Recurrent and metastatic disease | LF | ⚠ | ⚠ | ✔ | ⚠ | ✘ |

BILIARY TREE AND GALLBLADDER CANCER (<2% of exam)

| | | | | | | |
|----------------------------------|----|---|---|---|---|---|
| Local-regional disease | LF | ⚠ | ✔ | ✔ | ⚠ | ⚠ |
| Recurrent and metastatic disease | LF | ⚠ | ⚠ | ✔ | ⚠ | ✘ |

COLORECTAL CANCER (4.5% of exam)

| | | | | | | |
|----------------------------------|--|---|---|---|---|---|
| Colon cancer | | | | | | |
| Local-regional disease | | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Recurrent and metastatic disease | | ✔ | ✔ | ✔ | ✔ | ⚠ |

| | | | | | | |
|----------------------------------|--|---|---|---|---|---|
| Rectal cancer | | | | | | |
| Local-regional disease | | ✔ | ✔ | ✔ | ✔ | ⚠ |
| Recurrent and metastatic disease | | ✔ | ✔ | ✔ | ✔ | ⚠ |

ESOPHAGEAL CANCER (<2% of exam)

| | | | | | | |
|----------------------------------|--|---|---|---|---|---|
| Local-regional disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Recurrent and metastatic disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |

GASTRIC CANCER (<2% of exam)

| | | | | | | |
|-------------------------------------|--|---|---|---|---|---|
| Resectable disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Unresectable and metastatic disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |

HEPATOCELLULAR CANCER (<2% of exam)

| | | | | | | |
|----------------------------------|----|---|---|---|---|---|
| Resectable disease | LF | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Unresectable, liver-only disease | | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Metastatic disease | LF | ✔ | ✔ | ✔ | ⚠ | ✘ |

GASTROINTESTINAL NEUROENDOCRINE TUMORS (<2% of exam)

| | | | | | | |
|--|----|---|---|---|---|---|
| Gastrointestinal neuroendocrine tumors | LF | ✔ | ✔ | ✔ | ⚠ | ⚠ |
|--|----|---|---|---|---|---|

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

◐ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| GASTROINTESTINAL CANCER <i>continued...</i> (13.5% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|-----------|---------|------------------------------|--|-----------------------------------|
|--|-----------|---------|------------------------------|--|-----------------------------------|

PANCREATIC CANCER (3% of exam)

| | | | | | |
|----------------------------------|---|---|---|---|---|
| Resectable disease | ✔ | ✔ | ✔ | ◐ | ◐ |
| Unresectable disease | ✔ | ✔ | ✔ | ◐ | ◐ |
| Metastatic and recurrent disease | ✔ | ✔ | ✔ | ◐ | ◐ |

SMALL BOWEL AND APPENDICEAL CANCER (<2% of exam)

| | | | | | | |
|--------------------|----|---|---|---|---|---|
| Small bowel cancer | LF | ◐ | ◐ | ✔ | ◐ | ✘ |
| Appendiceal cancer | LF | ◐ | ◐ | ◐ | ◐ | ✘ |

| SKIN CANCER, SARCOMAS, AND UNKNOWN PRIMARY SITE (6% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|--|-----------|---------|------------------------------|--|-----------------------------------|
|--|-----------|---------|------------------------------|--|-----------------------------------|

MELANOMA (2% of exam)

| | | | | | |
|--|---|---|---|---|---|
| Localized melanoma | ✔ | ✔ | ✔ | ◐ | ◐ |
| Regional nodal and in-transit metastasis | ◐ | ◐ | ✔ | ◐ | ◐ |
| Metastatic disease | ✔ | ✔ | ✔ | ◐ | ◐ |

OTHER SKIN CANCERS (<2% of exam)

| | | | | | | |
|---|----|---|---|---|---|---|
| Squamous cell and basal cell cancer of the skin | | | | | | |
| Local-regional disease | LF | ◐ | ◐ | ◐ | ✘ | ✘ |
| Recurrent and metastatic disease | LF | ◐ | ◐ | ◐ | ◐ | ✘ |
| Merkel cell carcinoma | LF | ◐ | ◐ | ◐ | ✘ | ✘ |

BONE AND SOFT-TISSUE SARCOMAS (<2% of exam)

| | | | | | | |
|---------------------------|----|---|---|---|---|---|
| Localized primary disease | LF | ◐ | ◐ | ◐ | ◐ | ✘ |
| Local disease recurrence | LF | ◐ | ◐ | ◐ | ◐ | ✘ |
| Metastatic disease | LF | ◐ | ◐ | ✔ | ◐ | ✘ |

| | | | | | | |
|---------------------------------------|----|---|---|---|---|---|
| Gastrointestinal stromal tumor (GIST) | | | | | | |
| Local-regional disease | LF | ◐ | ◐ | ✔ | ◐ | ◐ |
| Recurrent and metastatic disease | LF | ◐ | ◐ | ✔ | ◐ | ◐ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – **Low Frequency:** No more than 20% of questions will address topics with this designation, regardless of task or importance.

| SKIN CANCER, SARCOMAS, AND UNKNOWN PRIMARY SITE <i>continued...</i> (6% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

UNKNOWN PRIMARY SITE (2% of exam)

| | | | | | |
|----------------------|---|---|---|---|---|
| Unknown primary site | ✔ | ✔ | ✔ | ⚠ | ✘ |
|----------------------|---|---|---|---|---|

| HEAD, NECK, THYROID, AND CENTRAL NERVOUS SYSTEM MALIGNANCIES (4% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (<2% of exam)

| | | | | | |
|---------------------------------------|---|---|---|---|---|
| Human papillomavirus–positive disease | | | | | |
| Local-regional disease | ⚠ | ⚠ | ✔ | ⚠ | ✘ |
| Recurrent and metastatic disease | ⚠ | ⚠ | ✔ | ⚠ | ✘ |

| | | | | | |
|---------------------------------------|---|---|---|---|---|
| Human papillomavirus–negative disease | | | | | |
| Local-regional disease | ⚠ | ⚠ | ✔ | ⚠ | ✘ |
| Recurrent and metastatic disease | ⚠ | ⚠ | ✔ | ⚠ | ✘ |

SALIVARY GLAND TUMORS (<2% of exam)

| | | | | | | |
|-----------------------|----|---|---|---|---|---|
| Salivary Gland Tumors | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
|-----------------------|----|---|---|---|---|---|

THYROID CANCER (<2% of exam)

| | | | | | | |
|------------|----|---|---|---|---|---|
| Papillary | LF | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Medullary | LF | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |
| Anaplastic | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |

NASOPHARYNGEAL CARCINOMA (<2% of exam)

| | | | | | | |
|----------------------------|----|---|---|---|---|---|
| Local and regional disease | LF | ⚠ | ⚠ | ✔ | ⚠ | ⚠ |
| Metastatic disease | LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |

✔ – **High Importance:** At least 75% of questions will address topics and tasks with this designation.

⚠ – **Medium Importance:** No more than 25% of questions will address topics and tasks with this designation.

✘ – **Low Importance:** No questions will address topics and tasks with this designation.

LF – Low Frequency: No more than 20% of questions will address topics with this designation, regardless of task or importance.

| HEAD, NECK, THYROID, AND CENTRAL NERVOUS SYSTEM MALIGNANCIES <i>continued...</i> (4% of exam) | Diagnosis | Testing | Treatment/ Care Decisions | Risk Assessment/ Prognosis/ Epidemiology | Pathophysiology/ Basic Science |
|---|-----------|---------|------------------------------|--|-----------------------------------|
|---|-----------|---------|------------------------------|--|-----------------------------------|

CENTRAL NERVOUS SYSTEM MALIGNANCIES (<2% of exam)

| Primary central nervous system lesions | | | | | |
|--|---|---|---|---|---|
| High-grade gliomas (astrocytoma and glioblastoma) | ✔ | ✔ | ✔ | ⚠ | ⚠ |
| Oligodendroglioma and other central nervous system lesions LF | ⚠ | ⚠ | ⚠ | ⚠ | ✘ |
| Metastatic central nervous system lesions | | | | | |
| Parenchymal metastases | ✔ | ✔ | ✔ | ⚠ | ✘ |
| Meningeal metastases LF | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ |